Repeat transcatheter aortic valve implantation using a latest generation balloon-expandable device for treatment of failing transcatheter heart valves
Authors:
- Andreas SchaeferASAndreas Schaefer
- Hendrik TreedeHTHendrik Treede
- Moritz SeiffertMSMoritz Seiffert
- Florian DeuschlFDFlorian Deuschl
- Niklas SchoferNSNiklas Schofer
- Yvonne SchneebergerYSYvonne Schneeberger
- Stefan BlankenbergSBStefan Blankenberg
- Hermann ReichenspurnerHRHermann Reichenspurner
- Ulrich SchaeferUSUlrich Schaefer
- Lenard ConradiLCLenard Conradi
Open Access
- 15 January 2016
- journal article
- research article
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 11 (1) , 2
Abstract
Paravalvular leakage (PVL) is a known complication of transcatheter aortic valve implantation (TAVI) and is associated with poor outcome. Besides balloon-post-dilatation, valve-in-valve (ViV) procedures can be taken into consideration to control this complication. Herein we present initial experience with use of the latest generation balloon-expandable Edwards Sapien 3® (S3) transcatheter heart valve (THV) for treatment of failing THVs. Between 01/2014 and 12/2014 three patients (two male, age: 71–80 y, log EUROScore I: 11.89 – 32.63) with failing THVs were refered to our institution for further treatment. THV approach with secondary implantation of an S3 was chosen after mutual agreement of the local interdisciplinary heart team at an interval of 533–1119 days from the index procedure. The performed procedures consisted of: S3 in Sapien XT, JenaValve and CoreValve. Successful transfemoral implantation with significant reduction of PVL was achieved in all cases. No intraprocedural complications occured regarding placement of the S3 with a postprocedural effective orifice area (EOA) of 1.5–2.5 cm2 and pressure gradients of max/mean 14/6–36/16 mmHg. 30-day mortality was 0 %. At the latest follow-up of 90–530 days, all patients are alive and well with satisfactory THV function. Regarding VARC-2 criteria one major bleeding and one TIA was reported. In the instance of moderate or severe aortic regurgitation after TAVI, S3 ViV deployment is an excellent option to reduce residual regurgitation to none or mild. For further assertions concerning functional outcomes long-term results have to be awaited.Keywords
This publication has 18 references indexed in Scilit:
- Use of a balloon-expandable transfemoral sheath in a TAVI cohort with complex access site - a propensity score matched analysisEuroIntervention, 2015
- TRINITY heart valve prosthesis: a novel repositionable and retrievable transapical transcatheter aortic valve systemEuroIntervention, 2015
- Noncontrast 3D CMR Imaging for Aortic Valve Annulus Sizing in TAVRJACC: Cardiovascular Imaging, 2015
- Valve-in-valve transfemoral TAVR: Sapien 3 valve within a failed core valve bioprosthesisEuropean Heart Journal, 2014
- Transcatheter Aortic-Valve Replacement with a Self-Expanding ProsthesisNew England Journal of Medicine, 2014
- Single-centre experience with next-generation devices for transapical aortic valve implantation†European Journal of Cardio-Thoracic Surgery, 2014
- Edwards Sapien XT valve placement as treatment option for aortic regurgitation after transfemoral CoreValve implantation: a multicenter experienceClinical Research in Cardiology, 2013
- A comprehensive review of the PARTNER trialThe Journal of Thoracic and Cardiovascular Surgery, 2013
- Impact of Paravalvular Leakage on Outcome in Patients After Transcatheter Aortic Valve ImplantationJACC: Cardiovascular Interventions, 2012
- Interventional options for severe aortic regurgitation after transcatheter aortic valve implantation: balloons, snares, valve-in-valveClinical Research in Cardiology, 2012